Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Vanilloids in pancreatic cancer: potential for chemotherapy and pain management

Open access
Hartel, M, di Mola, F F, Selvaggi, F, Mascetta, G, Wente, M N, Felix, K, Giese, N A, Hinz, U, Di Sebastiano, P, Büchler, M W, Friess, H · 2006 · Gut

Abstract

Background: Success of chemotherapy and alleviation of pain are frequently less than optimal in pancreatic cancer patients, leading to increasing interest in new pharmacological substances, such as vanilloids. Our study addressed the question of whether vanilloids influence pancreatic cancer cell growth, and if vanilloids could be used for pain treatment via the vanilloid 1 receptor (VR1) in pancreatic cancer patients. Methods: In vitro, the effect of resiniferatoxin (vanilloid analogue) on apoptosis and cell growth in pancreatic cancer cells—either alone, combined with 5-fluorouracil (5-FU), or combined with gemcitabine—was determined by annexin V staining, FACS analysis, and MTT assay, respectively. VR1 expression was evaluated on RNA and protein level by quantitative polymerase chain reaction and immunohistochemistry in human pancreatic cancer and chronic pancreatitis. Patient characteristics—especially pain levels—were registered in a prospective database and correlated with VR1 expression. Results: Resiniferatoxin induced apoptosis by targeting mitochondrial respiration and decreased cell growth in pancreatic cancer cells without showing synergistic effects with 5-FU or gemcitabine. Expression of VR1 was significantly upregulated in human pancreatic cancer and chronic pancreatitis. VR1 expression was related to the intensity of pain reported by cancer patients but not to the intensity of pain reported by patients with chronic pancreatitis. Conclusions: Resiniferatoxin induced apoptosis in pancreatic cancer cells indicates that vanilloids may be useful in the treatment of human pancreatic cancer. Furthermore, vanilloid might be a novel and effective treatment option for neurogenic pain in patients with pancreatic cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.2005.073205

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 161

Metadata

Authors
Hartel, M., di Mola, F. F., Selvaggi, F., Mascetta, G., Wente, M. N., Felix, K., Giese, N. A., Hinz, U., Di Sebastiano, P., Büchler, M. W., & Friess, H.
Venue
Gut
Publisher
BMJ
Published
2005-09-20
Volume
55
Issue
4
Pages
519-528
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2123837094
Cited by
161
References
1
FWCI
3.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. https://app.cochat.ai/papers/10.1136/gut.2005.073205
The paper
Hartel, M., di Mola, F. F., Selvaggi, F., Mascetta, G., Wente, M. N., Felix, K., Giese, N. A., Hinz, U., Di Sebastiano, P., Büchler, M. W., & Friess, H. (2006). Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut. https://doi.org/10.1136/gut.2005.073205

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.